Otsuka Holdings (4578.JP) rose 4.24% for the day as the drug received FDA approval

AASTOCKS
2025.11.26 08:03

Otsuka Holdings (4578.JP) today (26th) closed at 9,027 yen, up 4.24% for the day. Otsuka Pharmaceutical and its U.S. subsidiary announced that "Sibrelimab" has received fast track approval from the U.S. FDA for the treatment of adult IgA nephropathy with proteinuria reduction, making it the world's first drug targeting APRIL. The day before, the company announced that it had submitted a new drug application to the FDA for "Centanafadine," a treatment for attention deficit hyperactivity disorder (ADHD), and believes that related research and development has made positive progress as patents for major antipsychotic drugs and kidney disease treatments expire

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer